4th International RASopathies Symposium, July 17-19, 2015, Seattle, WA

**Speakers and Moderators**

|  |  |
| --- | --- |
| Brage **Andresen**, PhD, University of S. Denmark | Alternative splicing therapeutics – HRAS |
| Annette **Bakker**, PhD, Children’s Tumor Foundation, NY | Co-Moderator, Collaborations, Industry, and Funding; Business model |
| Pinar **Bayrak-Toydemir**, MD, PhD, University of Utah | RASA 1 |
| Tammy **Bowers**, NSML/LEOPARD syndrome Advocate, UT | Co-Moderator, Advocates’ Panel |
| Emma **Burkitt-Wright**, MBChB, St. Mary’s Hospital, Manchester, UK | Co-Moderator, Clinical rails in RASopathies: Design, Endpoints, and Results |
| Kathryn **Chatfield**, MD, PhD, University of Colorado | Cardiac manifestations |
| Florent **Elefteriou**, PhD, Vanderbilt University, VA | Co-Moderator, Preclinical Studies |
| Michael **Fisher**, MD, Children’s Hospital Philadelphia, PA | Agents targeting RAS/MAPK in clinical development: current status |
| David **Franz**, MD, Cincinnati Children’s Hospital, OH | TSC |
| Bruce **Gelb**, MD, Mt. Sinai School of Medicine, NY | Drug target screening – Drosophila |
| Anne **Goriely**, PhD, University of Oxford, UK | Co-Moderator, Preclinical Studies |
| Bruce **Korf**, MD, PhD, University of Alabama, Birmingham, AL | Cancer |
| Shivaani **Kummar**, MD, National Cancer Institute, MD | Performing clinical trials with small patient numbers |
| Frank **McCormick**, PhD, FRS, DSc (Hon), University of California, San Francisco, CA | Keynote Speaker |
| Scott **Plotkin**, MD, PhD, Massachusetts General Hospital, MA | Co-Moderator, Clinical rails in RASopathies: Design, Endpoints, and Results; Trial design using individualized endpoints |
| Katherine A. **Rauen**, University of California at Davis, CA | MEK inhibitors for strength |
| Karlyne **Reilly**, PhD, National Cancer Institute, MD | NF1 preclinical models and trials |
| Amy **Roberts**, MD, Children’s Hospital Boston, MA | TRND study |
| Abby **Sandler**, PhD, National Cancer Institute, MD | NCI Rare Disease Initiative |
| Lisa **Schill**, BS, RASopathies Network USA, NJ | Co-Moderator, Collaborations, Industry, and Funding |
| Lisa **Schoyer**, RASopathies Network USA, Altadena, CA | Co-Moderator, Advocates’ Panel |
| Dawn **Siegel**, MD, Children’s Hospital of Wisconsin | Co-Moderator, RASopathies Cousins |
| David **Stevenson**, MD, University of Utah | Symposium Co-Chair; Overview of the RASopathies |
| Karin **Walsh**, PsyD, Children’s National Medical Center, WDC | Pilot trial of effect of RAS/MAPK inhibitors on neurocognitive function in NF1 |
| Brigitte **Widemann**, MD, National Cancer Institute | Symposium Co-Chair; Phase 1 trial of AZD6244 in NF1 tumors |